Skip to main content

Clinical Trial Search Results

Clinical Trial Search Results

Showing 100-108 out of 282 results.
NCT04811092

HYPERION A Phase 3, Randomized, Doubleblind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial
Hypertension (PAH) Therapy in Newly Diagnosed Intermediate-and High-risk PAH Patients

Icon for trial | A011-13 HYPERION A Phase 3, Randomized, Doubleblind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial 
Hypertension (PAH) Therapy in Newly Diagnosed Intermediate-and High-risk PAH Patients

This study is currently enrolling.

Pulmonary arterial hypertension (PAH) is a disease affecting the blood vessels of the lungs. PAH leads to increased pressure in the blood vessels of the lungs which further leads to straining of the right side of the heart. You ...

NCT05147805

Insmed Incorporated / “A Phase 2b, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Arterial Hypertension”

Icon for trial | INS 1009-202 Insmed Incorporated / “A Phase 2b, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Arterial

This study is currently enrolling.

'Insmed Incorporated / “A Phase 2b, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants with Pul ...

NCT03321734

INTERMITTENT HYPOXIA AND CAFFEINE IN INFANTS BORN PRETERM

Icon for trial | R01HD089289 INTERMITTENT HYPOXIA AND CAFFEINE IN INFANTS BORN PRETERM

This study is currently enrolling.

You are being asked to allow your baby to be in this research study because your premature baby was given the medication caffeine as treatment for his/her immature breathing in the neonatal intensive care unit (NICU). Particip ...

NCT06026410

KO-2806-001: Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients with Advanced Solid Tumors

Icon for trial | KO-2806-001 KO-2806-001: Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered as Monotherapy and in Combination The

This study is currently enrolling.

The purposes of this study are to: • Determine the highest tolerable dose of KO-2806 given orally (by mouth) in combination with cabozantinib. • Determine whether KO-2806 has an antitumor effect (reduces the size of your tumor ...